Research Library / Mitochondrial / NAD+
Mitochondrial researchNAD+
Nicotinamide adenine dinucleotide
A ubiquitous coenzyme rather than a peptide. The listed community example (common subcutaneous range) describes 50–100 mg per administration, two or three times weekly, via subcutaneous; this is not a validated dosing recommendation. An illustrative 500 mg vial at an assumed 5 mL final volume yields 100 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 500mg
- Assumed final volume
- 5mL · not an amount to add
- Concentration
- 100mg/mL · conditional arithmetic
- One U-100 marking
- 1000mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryClinicalTrials.govNo established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryFDA sterile-compounding safety alertReported schedule context
- Range
- 50–100 mg
- Frequency
- Two or three times weekly
- Route
- Subcutaneous or intravenous
- Reported half-life
- Variable by route
- Reported cycle
- Route- and format-dependent
Infusion and subcutaneous schedules should not be treated as equivalent.
Cross-reference reviewed October 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Common subcutaneous range | 50–100 mg | 50–100 mg per administration | Two or three times weekly | Morning or early day | Subcutaneous | Community-reported |
| Common infusion schedule | 250–500 mg | 250–500 mg/session | Intermittent sessions | Clinic-timed | Intravenous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
10 example portions per vial
10 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
50 mg concentration example · 100 mg/mL · 0.5 mL · 50 units
This produces 100 mg/mL, so 50 mg equals 0.50 mL (50 U-100 units). Community/provider instructions also report other concentrations; verify vial capacity, labeled solvent, final mixed volume, route, and beyond-use time. NAD+ free acid, salts, and buffered products must be distinguished. Provider/community preparations and supplier PBS data do not validate every 100 mg/mL example. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
500 mg (hypothetical) · 5 mL assumed final solution volume; diluent product-specific · Common subcutaneous range
Vial counts and final solution totals below use the selected 500 mg example at 5 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 50–100 mg | Two or three times weekly | 100–300 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 400–1200 mg | 1–3 × 500 mg |
| 8 weeks | 800–2400 mg | 2–5 × 500 mg |
| 12 weeks | 1200–3600 mg | 3–8 × 500 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 5–15 mL | Not established |
| 8 weeks | 10–25 mL | Not established |
| 12 weeks | 15–40 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 8–12 |
| 8 weeks | 16–24 |
| 12 weeks | 24–36 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 5–10 administrations
8 weeks: 5–10 administrations
12 weeks: 5–10 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- NAD+ · Nicotinamide adenine dinucleotide
- Evidence / status
- Limited human. No FDA-approved anti-aging indication
- Clinical route, frequency & duration
Evidence landscape: No established clinical dose, route or frequency
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- Cellular energy, recovery, fatigue, and longevity or wellness discussions.
- Reported timing / route
- Two or three times weekly · Subcutaneous or intravenous. Schedule-specific timing remains in the Community tab.
- Reported half-life
- Variable by route · community-reference context, not a shelf life.
- Reported cycle
- Route- and format-dependent. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
NAD+ free acid, salts, and buffered products must be distinguished. Provider/community preparations and supplier PBS data do not validate every 100 mg/mL example.
Other vehicles and approaches discussed
Final pH, final volume, container capacity and excipients require product-specific information. Cloudiness is reported with BAC water; no home acid/bicarbonate adjustment or universal PBS/BAC ratio is validated here.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Buffer / pH / high-concentration preparation concern
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Buffer / pH / high-concentration preparation concern
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Cellular redox coenzyme and metabolic substrate
A ubiquitous coenzyme rather than a peptide. Direct parenteral NAD+ has a thinner evidence base than oral precursor research.
Community-reported purpose
Cellular energy, recovery, fatigue, and longevity or wellness discussions.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Evidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceEvidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Safety depends on route, formulation and exposure. FDA warns against food-grade ingredients for sterile NAD+ preparations and reports chills, shaking, vomiting and fatigue after injectable products, consistent with endotoxin contamination. This is a product-quality warning, not proof that every NAD+ product is contaminated. Cellular importance alone does not prove clinical benefit.
Development and regulatory status
No FDA-approved anti-aging indication
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is NAD+?
A ubiquitous coenzyme rather than a peptide. Direct parenteral NAD+ has a thinner evidence base than oral precursor research.
Cellular redox coenzyme and metabolic substrate
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Route- and format-dependent
Which diluent and storage period should this material use?
NAD+ free acid, salts, and buffered products must be distinguished. Provider/community preparations and supplier PBS data do not validate every 100 mg/mL example.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeClinicalTrials.gov: Evidence landscape
- Clinical / regulatory / evidence landscapeFDA sterile-compounding safety alert: Evidence landscape
- Laboratory supplier or secondary reference — product-specificCayman NAD+ free-acid specifications
- Community/vendor report — unvalidatedNAD+ cloudiness discussion
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.